Search

Your search keyword '"Burke, TG"' showing total 74 results

Search Constraints

Start Over You searched for: Author "Burke, TG" Remove constraint Author: "Burke, TG"
74 results on '"Burke, TG"'

Search Results

2. Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

3. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies

4. Synthesis and evaluation of a novel E-ring modified α-hydroxy keto ether analogue of camptothecin

5. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs

6. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity

7. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity

9. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo

11. Evidence for three morphotypes among anadromous Arctic char (Salvelinus alpinus) sampled in the marine environment.

12. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells.

13. Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

14. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.

15. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.

16. Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions.

17. The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

18. Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection.

19. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs.

20. Synthesis and evaluation of a novel E-ring modified alpha-hydroxy keto ether analogue of camptothecin.

21. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.

23. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity.

24. Treatment of thoracic disc herniation: evolution toward the minimally invasive thoracoscopic technique.

25. Microendoscopic posterior cervical foraminotomy: a cadaveric model and clinical application for cervical radiculopathy.

26. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo.

27. Lack of latex allergen contamination of solutions withdrawn from vials with natural rubber stoppers.

28. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.

29. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities.

30. Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation.

31. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins.

32. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

33. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles.

34. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.

35. Drug allergy assessment at a university hospital and clinic.

37. Fluorescence detection of the anticancer drug topotecan in plasma and whole blood by two-photon excitation.

38. Biomechanical comparison of the dewar and interspinous cervical spine fixation techniques.

39. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG).

40. Reduced albumin binding promotes the stability and activity of topotecan in human blood.

41. Thrombolytic-associated cholesterol emboli syndrome: case report and literature review.

43. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study.

44. Differential interactions of camptothecin lactone and carboxylate forms with human blood components.

45. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.

46. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.

47. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin.

49. Lipid bilayer partitioning and stability of camptothecin drugs.

50. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.

Catalog

Books, media, physical & digital resources